Information Provided By: 
Fly News Breaks for August 25, 2015
TEVA
Aug 25, 2015 | 08:17 EDT
Leerink believes that Teva's multiple is low, given what it sees as the company's "underappreciated specialty brand pipeline" and the "best in class generic pipeline" that it will have following the closing of its Allergan generics deal. The firm keeps an $83 price target and Outperform rating on the shares.
News For TEVA From the Last 2 Days
